A Gaithersburg biopharmaceutical company is working with an Alabama university to prepare its COVID-19 vaccine candidate for clinical trials.
Altimmune Inc. announced Monday it would work with the University of Alabama at Birmingham on the development of its single-dose, intranasal COVID-19 vaccine, which it calls AdCOVID.
The company plans to work with university investigators on studies of the vaccine in animals and the ability of the vaccine to provoke an immune response, with the goal of enabling early research in humans in the third quarter of this year.
Altimmune is also developing vaccines for seasonal and pandemic influenza and for inhalation anthrax.
Vipin K. Garg, president and CEO of Altimmune, said in a news release that the university was an ideal partner, adding that the company was founded in 1997 through a technology license from the university.